u/flair_enthusiast

Disagree. You are comparing doses across a small molecule and a peptide, which is not a comparison of anything.

Read the primary paper after arguing about the summary for a fortnight. The discussion section said almost the opposite of what the thread had concluded.

Added a sleep column late and immediately understood two of my worst weeks.

nobody owes anybody a starting weight

This. The absence of food and water timing restrictions is the practical difference people will actually notice.

GLP-1 receptor agonism acts both peripherally — insulin secretion in a glucose-dependent way, slowed gastric emptying — and centrally, on appetite regulation. The central component is the better explanation for sustained intake reduction.

a log with no dates is a story

Disagree with daily weighing. You are logging fluid, and the emotional cost is real for very little information.

Disagree with reading anything into that. One value, one morning, and you changed two other things in the same window.

Why this board is text only, since new members ask every week.

A photograph invites comparison on things nobody can control — lighting, posture, where you carry weight, what you looked like before any of this. Text invites description of what changed for you: the jacket, the stairs, the measurement, the month it took.

The result is a board where the posts are about people’s actual experience rather than about images, and where nobody is competing on the wrong axis. It was a deliberate choice, it has been challenged periodically, and every time it has been kept.

Is that from the publication or the press release?

Substantial weight loss independently moves lipids, liver enzymes and several other markers. Attributing a change to a compound while losing weight is confounded by design.

Right, and the payoff arrives around month six when a pattern becomes visible that nobody could hold in their head.

What did the tolerability table look like at that dose?

Correction: that is the oral peptide product, which is a different thing entirely. This one is a small molecule.

ATTAIN and ACHIEVE are the programmes to keep straight

Substantial weight loss independently moves lipids, liver enzymes and several other markers. Attributing a change to a compound while losing weight is confounded by design.

the tolerability profile reads broadly similar to the class

Repeat testing before acting is standard practice for a reason: regression to the mean does a lot of work on single outlying values.

It is a non-peptide small-molecule agonist at the GLP-1 receptor. That is a substantial medicinal chemistry achievement: getting a small molecule to activate a receptor evolved for a peptide ligand.

Text-only posting removes the comparison mechanism that makes image boards difficult, which is why this community adopted the rule and has kept it.

Why mechanism talk keeps misleading people, including me.

A mechanism tells you a direction. It does not tell you a magnitude, a timescale, or whether the pathway is operative at the exposures involved. "Receptor X is expressed in tissue Y" is a fact; "therefore effect Z in a person" is a hypothesis with several missing steps.

The corrective is boring and it works: ask whether the evidence is preclinical or human, ask what exposure was used, and read the limitations section before the abstract. Most of the confidently wrong posts on this board — several of them mine — skipped all three.

Spent an evening reading about small-molecule agonism at a peptide receptor. Genuinely interesting engineering.

Does the effect persist with continued dosing or does tolerance develop?

That study was in a rodent model. Worth stating, since the thread has been reading it as human data.

Correction: that is glucose-dependent insulin secretion, which is why hypoglycaemia risk is low as monotherapy. Not the same claim as you made.